Taking research to market
Queensland science is characterised by a high number of new companies arising from the cutting-edge research being undertaken at Queensland institutes.
The industry currently has around 100 companies, including:
A new US$200 million bio-venture fund, supported by global biopharmaceutical leader Eli Lilly and Company and managed by HealthCare Ventures LLC, supports the development and commercialisation of new biotechnology products from across the globe, including research and technology produced by Queensland's biotechnology industry.
Medical Research Commercialisation Fund
Queensland is also involved in the Medical Research Commercialisation Fund (MRCF), which provides a supportive investment environment to foster innovation emanating from Australian medical research institutes and allied research hospitals. The MRCF - alongside OneVentures Pty Ltd, Brandon Capital Partners and HealthCare Ventures - has made one of Australia's largest ever investments in a biotechnology start-up company. Queensland's Vaxxas Pty Ltd recently received A$15 million to further develop a revolutionary needlefree vaccine delivery system.
UniQuest is one of Australia's leading research commercialisation companies, specialising in global technology transfer and facilitating access for all business sectors to world class university expertise, intellectual property and facilities.
UniQuest's innovation portfolio includes the Gardasil vaccine, biotech IPO QRxPharma Ltd, the Triple P Positive Parenting Program, and University of Queensland's superconductor technology used in MRI machines.
Griffith Enterprise is the commercialisation and technology transfer office of Griffith University
Queensland offers opportunities for businesses to grow through investment in research and innovation. Learn more about the support services available in Queensland to help businesses and researchers commercialise their products.
Find out more:
Last updated 14 June 2012